Prediction of treatment outcomes in major depressive disorder

Expert Review of Clinical Pharmacology

Volumn 8, Issue 6, 2015, Pages 669-672

  Dunlop, Boadie W ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

biomarker; depression; moderator; neuroimaging; precision; prediction; treatment

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; C REACTIVE PROTEIN; ESCITALOPRAM; FLUORODEOXYGLUCOSE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NORTRIPTYLINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ANTERIOR INSULA; ANXIETY; ATTENTIONAL BIAS; ATYPICAL DEPRESSION; CINGULATE GYRUS; CLINICAL FEATURE; COGNITIVE THERAPY; DRUG EFFICACY; ELECTROENCEPHALOGRAPHY; FUNCTIONAL NEUROIMAGING; HUMAN; HYPERSOMNIA; INCREASED APPETITE; INFLAMMATION; LOWEST INCOME GROUP; MAJOR DEPRESSION; MEASUREMENT ACCURACY; NEUROIMAGING; OUTCOME ASSESSMENT; PANIC; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PSYCHOTHERAPY; REMISSION; REVIEW; RISK ASSESSMENT; SUICIDE; TREATMENT DURATION; TREATMENT OUTCOME; UNEMPLOYMENT; DEPRESSIVE DISORDER, MAJOR; GENETIC SCREENING; PATHOLOGY; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PROCEDURES; PROGNOSIS;

DEPRESSIVE DISORDER, MAJOR; ELECTROENCEPHALOGRAPHY; GENETIC TESTING; HUMANS; INFLAMMATION; NEUROIMAGING; PRECISION MEDICINE; PROGNOSIS; TREATMENT OUTCOME;

EID: 84946491234     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2015.1075390     Document Type: Review

References (22)

1. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med 2015;372:793-5
2. Craighead WE, Dunlop BW. Combination psychotherapy and antidepressant medication for depression: For whom, when and how. Ann Rev Psychol 2014;65:267-300
3. Simon GE, Perlis RH. Personalized medicine for depression: Can we match patients with treatments? Am J Psychiatry 2010;167:1445-55
4. Kemp AH, Gordon E, Rush AJ, Williams LM. Improving the prediction of treatment response in depression: integration of clinical, cognitive, psychophysiological, neuroimaging, and genetic measures. CNS Spectr 2008;13:1066-86
5. Jakubovski E, Bloch MH. Prognostic subgroups for citalopram response in the STAR∗D trial. J Clin Psychiatry 2014;75:738-47
6. Harmer CJ. Serotonin and emotional processing: does it help explain antidepressant drug action? Neuropharmacol 2008;55:1023-8
7. Henkel V, Mergl R, Allgaier A-K, et al. Treatment of depression with atypical features: a meta-analytic approach. Psychiatry Res 2006;141:89-101
8. Papakostas GI, Stahl SM, Krishen A, et al. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies. J Clin Psychiatry 2008;69:1287-92
9. Hasler G, Drevets WC, Manji HK, Charney DS. Discovering endophenotypes for depression. Neuropsychopharmacol 2004;29:1765-81
10. Dunlop BW, Mayberg HS. Neuroimaging-based biomarkers for treatment selection in major depressive disorder. Dialogues Clin Neurosci 2014;16:507-18
11. Breitenstein B, Scheuer S, Holsboer F. Are there meaningful biomarkers of treatment response for depression? Drug Discov Today 2014;19:539-61
12. Uher R, Tansey KE, Drew T, et al. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am J Psychiatry 2014;171:1278-86
13. Leuchter AF, Cook IA, Gilmer WS, et al. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder. Psychiatry Res 2009;169:132-8
14. Kaddurah-Daouk R, Boyle SH, Matson W, et al. Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: A proof of concept. Transl Psychiatry 2011;1:e26
15. Hall-Flavin DK, Winner JG, Allen JD, et al. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenet Genomics 2013;23:535-48
16. Impact of genesight psychotropic on response to psychotropic treatment in outpatients suffering from a major depressive disorder (MDD) and having had an inadequate response to at least one psychotropic medication included in genesight psychotropic (RCT). Available from: https://clinicaltrials.gov/ct2/show/NCT02109939
17. Siegle GJ, Thompson WK, Collier A, et al. Toward clinically useful neuroimaging in depression treatment: prognostic utility of subgenual cingulate activity for determining depression outcome in cognitive therapy across studies, scanners, and patient characteristics. Arch Gen Psychiatry 2012;69:913-24
18. McGrath CL, Kelley ME, Holtzheimer PE, et al. Toward a neuroimaging treatment selection biomarker for major depressive disorder. JAMA Psychiatry 2013;70:821-9
19. Dunlop BW, Kelley ME, McGrath CL, et al. Preliminary findings supporting insula metabolic activity as a predictor of outcome to psychotherapy and medication treatments for depression. J Neuropsychiatry Clin Neurosci 2015. [Epub ahead of print]
20. McGrath CL, Kelley ME, Dunlop BW, et al. Pretreatment brain states identify likely nonresponse to standard treatments for depression. Biol Psychiatry 2014;76:527-35
21. Dunlop BW, Binder EB, Cubells JF, et al. Predictors of remission in depression to individual and combined treatments (PReDICT): Study protocol for a randomized controlled trial. Trials 2012;13:106
22. Felger JC, Miller AH. Cytokine effects on basal ganglia and dopamine function: the subcorticol source of inflammatory malaise. Front Neuroendocrinol 2012;33:315-27